What the Doctors Say
We are deeply indebted to PCF for more than 10 years of generous support, which has allowed us to offer new therapies and genomic technologies to children in need.”
Because of PCF funding, we can now translate our FLT3 CAR T-cell immunotherapy from promising lab results to the clinic — a significant potential breakthrough for high-risk childhood leukemias.”
PCF support has allowed us to offer novel therapies to children with relapsed cancer, begin ground-breaking trials for inoperable brain tumors, and examine the immune micro-environment of pediatric solid tumors.”
